Entity

Time filter

Source Type


Xiao-Ying C.,Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention | Xiao-Ying C.,Shandong Agricultural University | Zhi-Jing X.,Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention | Zhi-Jing X.,Shandong Agricultural University | And 6 more authors.
Journal of Wildlife Diseases | Year: 2011

We isolated three new parvovirus variants in China. The isolate from a blue fox was related to feline parvovirus, but possessed a mutation of VP2 residue A300P. Isolates from a raccoon dog and a masked civet were antigenically similar to canine parvovirus-2a but had a substitution of VP2 residue G300S. © Wildlife Disease Association 2011. Source


Li Y.,Chinese Peoples Armed Police forces Academy | Shi X.L.,CAS Beijing National Laboratory for Molecular | Shi X.L.,CAS Institute of Chemistry | Liu H.L.,Chinese Peoples Armed Police forces Academy | And 6 more authors.
Science China Chemistry | Year: 2010

The interaction between the cell adhesion molecule CD11b and its ligand ICAM-1 plays an important role in inflammatory responses in the disease of atherosclerosis. Atorvastatin is a commonly prescribed statin drug which has been considered as one of the most potent therapeutic agents for atherosclerosis due to its lipid-lowering effect. Recently, there is a growing body of evidence that atorvastatin has anti-inflammatory effect. We have applied the advanced method of live-cell single-molecule force spectroscopy to investigate the effect of atorvastatin on adhesion force between ICAM-1 and CD11b. Our result showed that single-molecule binding force of ICAM-1 and CD11b detected by AFM in the living cells was about 40 pN, and atorvastatin did not affect this force by blocking ICAM-1 or CD11b. This was different from the ICAM-1 monoclonal antibody, which could directly reduce the binding force of ICAM-1 and CD11b. Flow cytometry results revealed that atorvastatin pretreatment decreased the ICAM-1 expression in TNF-αactivated H.UVECs which may contribute to its anti-inflammatory effect. The study provides a new approach to study anti-inflammatory mechanism for clinic drugs. © Science China Press and Springer-Verlag Berlin Heidelberg 2010. Source


Zhao X.,State Key Laboratory of Pathogen and Biosecurity | Zhao X.,Beijing Institute of Pharmacology and Toxicology | Sun J.,Shenyang Pharmaceutical University | Sun L.,Shenyang Pharmaceutical University | And 3 more authors.
Bioanalysis | Year: 2015

Background: While HIV-1 TAT peptide-conjugation shows great promise on improving intracellular delivery of biotherapeutics in vitro and in vivo, quantification of TAT-fusion therapeutics in biological matrices represents a daunting challenge. Materials & methods: A sensitive MS approach for accurate quantification of intact TAT-fusion protein/polypeptide in plasma was developed. i) A semi-automated 96-well ion-exchange solid phase extraction was developed; ii) a rapid LC separation on C4 was devised; iii) a TAT-fusion analog was constructed as internal standard. Results: We reported that low percentage of supercharging reagents enabled a significant sensitivity improvement of MS for intact TAT-fusion protein/polypeptide analysis. We showed a proof of concept by successfully developing a sensitive LC/MRM-MS method for quantifying GAP161, a TAT-conjugating RasGAP mimics, in rat plasma. Conclusion: This work represents the first quantification of TAT-fusion therapeutics in biological samples by an LC-MS based method. © 2015 Future Science Ltd. Source


Lee C.M.,Novartis | Xie X.,Novartis | Zou J.,Novartis | Zou J.,CAS Wuhan Institute of Virology | And 9 more authors.
Journal of Virology | Year: 2015

Flavivirus NS4A protein induces host membrane rearrangement and functions as a replication complex component. The molecular details of how flavivirus NS4A exerts these functions remain elusive. Here, we used dengue virus (DENV) as a model to characterize and demonstrate the biological relevance of flavivirus NS4A oligomerization. DENV type 2 (DENV-2) NS4A protein forms oligomers in infected cells or when expressed alone. Deletion mutagenesis mapped amino acids 50 to 76 (spanning the first transmembrane domain [TMD1]) of NS4A as the major determinant for oligomerization, while the N-terminal 50 residues contribute only slightly to the oligomerization. Nuclear magnetic resonance (NMR) analysis of NS4A amino acids 17 to 80 suggests that residues L31, L52, E53, G66, and G67 could participate in oligomerization. Ala substitution for 15 flavivirus conserved NS4A residues revealed that these amino acids are important for viral replication. Among the 15 mutated NS4A residues, 2 amino acids (E50A and G67A) are located within TMD1. Both E50A and G67A attenuated viral replication, decreased NS4A oligomerization, and reduced NS4A protein stability. In contrast, NS4A oligomerization was not affected by the replication-defective mutations (R12A, P49A, and K80A) located outside TMD1. trans complementation experiments showed that expression of wild-type NS4A alone was not sufficient to rescue the replication-lethal NS4A mutants. However, the presence of DENV-2 replicons could partially restore the replication defect of some lethal NS4A mutants (L26A and K80A), but not others (L60A and E122A), suggesting an unidentified mechanism governing the outcome of complementation in a mutant-dependent manner. Collectively, the results have demonstrated the importance of TMD1-mediated NS4A oligomerization in flavivirus replication. © 2015, American Society for Microbiology. Source


Lu H.-J.,Key Laboratory of Jilin Province for Zoonosis Prevention and Control | Qian J.,Key Laboratory of Jilin Province for Zoonosis Prevention and Control | Kargbo D.,Ministry of Health and Sanitation | Zhang X.-G.,U.S. Center for Disease Control and Prevention | And 18 more authors.
Emerging Infectious Diseases | Year: 2015

During 2014–2015, an outbreak of Ebola virus disease (EVD) swept across parts of West Africa. The China Mobile Laboratory Testing Team was dispatched to support response efforts, during September 28–November 11, 2014, they conducted PCR testing on samples from 1,635 suspected EVD patients. Of those patients, 50.4% were positive, of whom 84.6% lived within a 3-km zone along main roads connecting rural towns and densely populated cities. The median time from symptom onset to testing was 5 days. At testing, 75.7% of the confirmed patients had fever, and 94.1% reported at least 1 gastrointestinal symptom, all symptoms, except rash and hemorrhage, were more frequent in confirmed than nonconfirmed patients. Virus loads were significantly higher in EVD patients with fever, diarrhea, fatigue, or headache. The case-fatality rate was lower among patients 15–44 years of age and with virus loads of <100,000 RNA copies/mL. These findings are key for optimizing EVD control and treatment measures. © 2015, Centers for Disease Control and Prevention (CDC). All rights reserved. Source

Discover hidden collaborations